

For Immediate Release:

September 16, 2009

Contact:

Mary Kuramoto

513-579-9911 x 2523

m.kuramoto@medpace.com**Medpace therapeutic expert, David G. Orloff, MD, to present at the next Drug Information Association (DIA) conference, September 23-24, 2009.**

CINCINNATI, OH, September 16, 2009 - Medpace, Inc., a leading global full-service clinical research organization (CRO), today announced that Dr. David G. Orloff, Executive Director, Regulatory Affairs, will speak at the next Drug Information Association (DIA) meeting in Washington, DC on September 23-24. The agenda for this meeting is "Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science." Dr. Orloff's presentation September 23 will address "Alternate Clinical Study Approaches to a Cardiovascular Outcome Safety Study" as part of a session on novel clinical trial approaches.

Dr. David Orloff has been a regular presenter and commentator on current FDA Guidance on Diabetes and Cardiovascular risk assessment on an international level.

David Orloff, MD, is the Medpace Executive Director of Regulatory Affairs. He is the immediate past director of the Division of Metabolism and Endocrinology Products within the Center for Drug Evaluation and Research (CDER) of the FDA. Orloff is an endocrinologist and has 11 years of regulatory experience, with major foci in diabetes, obesity, and lipid metabolism. He has research experience in molecular and cellular biology and clinical endocrinology at the National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). He was a consultant to the National Cholesterol Education Program, Adult Treatment Plan III, and is an advisor to multiple pharmaceutical companies working in the metabolism and diabetes fields.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009, CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 1,000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at www.medpace.com